Diabetes News
FORT LEE, June 30, 2005 (PRNewswire-FirstCall) — Alpharma Inc. (NYSE: ALO - News), a leading global generic pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted final approval for the company's ANDA for glyburide/metformin HCl Tablets in the following dosages: 1.25 mg/250 mg; 2.5 mg/500 mg; and 5 mg/500 mg.
Alpharma's glyburide/metformin HCl Tablets are the AB-rated generic equivalent of Bristol-Myers Squibb's Glucovance® Tablets, a product indicated as an adjunct to diet and exercise in the treatment of type 2 diabetes. Glucovance® Tablet sales in 2004 were approximately $270 million. Glucovance® is a trademark of Lipha Corporation.
Alpharma press releases are also available at our website: http://www.alpharma.com.
Alpharma Inc. (NYSE: ALO - News) is a global generic pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma is a leading manufacturer of generic pharmaceutical products in the U.S., offering solid, liquid and topical pharmaceuticals. It is also one of the largest suppliers of generic solid dose pharmaceuticals in Europe, with a growing presence in Southeast Asia. Alpharma is among the world's leading producers of several important pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry, swine and cattle.
Statements made in this release include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Information on other significant potential risks and uncertainties not discussed herein may be found in the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2004.